...Stan better have some good news to impart upon us for the end of year Quarterly CC. Saying how exciting 2015 was for them, and how exciting 2016 will be just ain't going to cut it with the stock having been crushed by the Biotech collapse then completely devastated by the Convertible offering.
I have to blink twice every time I look at my computer screen and see the stock in $4's. Has he EVER mentioned "shareholder value"??
...what it means I don't know, but it is significant, nevertheless.
If Phase 3 Elderly is a success, I would think and hope that we would be looking at more than $20.00/share sometime in 2017.
If they get a combo Flu/RSV product to market in the next few years, and are still independent, then the sky is the limit in terms of share price.
...many other similar Biotechs are held by ETF's, but none have cratered like NVAX unfortunately.
..there is something unique that you fail to see - NVAX is down a whopping 44% year to date. Way worse than the XBI or IBB. That is a fact.
....a job well done.
Good post.....I'm sure after the Elderly Phase 3 is validated Pfizer or others would be interested in acquiring NVAX. The problem is, would NVAX want to be acquired. But everything has a price, and if the offer were large enough, one would hope that NVAX would accept it. Any thoughts on what price per share that would be??
.....a stock price that existed BEFORE Phase 2 success in RSV elderly, RSV maternal and QuadFlu. And now 2 ongoing Phase 3 trials. Nauseating and incomprehensible.
If they meet with success in their Phase 3 elderly, I for one hope the company is sold within 6 months after results. Who knows the number, but I am quite sure it would be at least $6 Billion+, and they would have multiple Pharma offers.
...hard to imagine with the stock at a shockingly low price of $5.00 With a successful Phase 3 Elderly, a Partnership and maybe accelerated approval for QuadFlu, we should be much higher. But in this bear market for Biotech, how much higher is anybody's guess.
January was extremely painful for shareholders. Almost a wipeout.
If RSV Elderly Phase 3 is positive, I think NVAX is sold in 2017. There aren't many multi $Billion Biotech franchises out there for Big Pharma to acquire.